Christopher M. Booth

Gastrointestinal promotility drugs in the critical care setting: a systematic review of the evidence.

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

Communication in the Toronto critical care community: important lessons learned during SARS.

Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest.

Severe acute respiratory syndrome and critical care medicine: the Toronto experience.

Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?

Pasteurella multocida bacteremia and tuboovarian abscess.

Does this patient with headache have a migraine or need neuroimaging?

Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.

Adjuvant chemotherapy for resected non-small cell lung cancer.

External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).

Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.

Fever and a rat bite.

Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?

Intractable nausea in a patient with metastatic colorectal cancer following insertion of a colonic stent.

Evolution of the randomized controlled trial in oncology over three decades.

Translating new medical therapies into societal benefit: the role of population-based outcome studies.

Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?

Presentation of nonfinal results of randomized controlled trials at major oncology meetings.

Call for clarity in the reporting of benefit associated with anticancer therapies.

Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study.

The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada.

Elements of confusion.

Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past.

Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation.

Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis.

Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada.

Progression-free survival: meaningful or simply measurable?

Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada.

Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancer.

Achieving the achievable in muscle-invasive bladder cancer.

Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study.

Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials.

Evaluation of treatment benefit: randomized controlled trials and population-based observational research.